Latest Breaking News On - Adamm brufsky - Page 1 : comparemela.com

BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024

Laying the Foundation for an Improved HR+/ HER2- Breast Cancer Treatment Paradigm

Investigators continue to evaluate HER2 expression as well as CDK4/6 inhibitor use for hormone receptor–positive/HER2-negative breast cancer.

Dr Brufsky on Unmet Needs and Unanswered Questions in HR+/HER2– Breast Cancer

Adam M. Brufsky, MD, PhD, FACP, discusses remaining questions and unmet needs following the FDA approval of capivasertib in combination with fulvestrant in hormone receptor–positive, HER2-negative breast cancer.

SABCS recap: Novel regimens, treatment de-escalation and 'catastrophic' financial burdens

Dr Brufsky on the FDA Approval of Capivasertib Plus Fulvestrant in PIK3CA/AKT1/PTEN-Altered HR+/HER2– Breast Cancer

Adam M. Brufsky, MD, PhD, FACP, discusses the significance of the FDA approval of capivasertib in combination with fulvestrant for patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alterations.